Cancer of the ovary

[71] LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR-ANALYSIS IN ADVANCED OVARIAN-CARCINOMA - THE GYNECOLOGIC-ONCOLOGY-GROUP EXPERIENCE [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) : 1138 - 1150

[72] Maintenance therapy in advanced ovarian cancer: Progression-free survival and clinical benefit [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) : 2451 - 2453

[73] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3194 - 3200

[74] Ozols RF, 2002, LANCET, V360, P2086, DOI 10.1016/S0140-6736(02)11984-2

[75] Recurrent ovarian cancer: Evidence-based treatment [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1161 - 1163

[76] The current role of gemcitabine in ovarian cancer [J]. SEMINARS IN ONCOLOGY, 2001, 28 (02) : 18 - 24

[77] Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: A case for recommending hysterectomy at surgical prophylaxis [J]. GYNECOLOGIC ONCOLOGY, 2001, 80 (02) : 176 - 180

[78] Parmar MKB, 2003, LANCET, V361, P2099

[79] Parmar MKB, 2002, LANCET, V360, P505

[80] NONGENITAL CANCERS METASTATIC TO THE OVARY [J]. GYNECOLOGIC ONCOLOGY, 1992, 44 (01) : 83 - 86

[71] LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR-ANALYSIS IN ADVANCED OVARIAN-CARCINOMA - THE GYNECOLOGIC-ONCOLOGY-GROUP EXPERIENCE [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) : 1138 - 1150

[72] Maintenance therapy in advanced ovarian cancer: Progression-free survival and clinical benefit [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) : 2451 - 2453

[73] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3194 - 3200

[74] Ozols RF, 2002, LANCET, V360, P2086, DOI 10.1016/S0140-6736(02)11984-2

[75] Recurrent ovarian cancer: Evidence-based treatment [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1161 - 1163

[76] The current role of gemcitabine in ovarian cancer [J]. SEMINARS IN ONCOLOGY, 2001, 28 (02) : 18 - 24

[77] Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: A case for recommending hysterectomy at surgical prophylaxis [J]. GYNECOLOGIC ONCOLOGY, 2001, 80 (02) : 176 - 180

[78] Parmar MKB, 2003, LANCET, V361, P2099

[79] Parmar MKB, 2002, LANCET, V360, P505

[80] NONGENITAL CANCERS METASTATIC TO THE OVARY [J]. GYNECOLOGIC ONCOLOGY, 1992, 44 (01) : 83 - 86